Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)
Clinical trial NCT04792567 · COMPLETED
Trial details
- NCT number
- NCT04792567
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-19
- Primary completion
- 2021-09-06
- Enrollment
- 41
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.